Ovarian cancer is one of the most common gynecological cancers in women with a low 5-year survival rate. Evaluation of hyaluronic acid-binding protein 1 (HABP1) level can provide important informat...
Ovarian cancer is one of the most common gynecological cancers in women with a low 5-year survival rate. Evaluation of hyaluronic acid-binding protein 1 (HABP1) level can provide important information for the diagnosis and treatment of ovarian cancer. In this study, we designed a novel HABP1 probe based on 99mTc-radiolabeled small-interference RNA (siRNA) for detecting HABP1 expression noninvasively in vivo, thereby providing a new method for its diagnosis and treatment. A specific siHABP1 was selected because of its targetability and silencing effect. A negative control siRNA (NCsiRNA) with no homology with the human genome was used. SiHABP1 and NCsiRNA were radiolabeled with 99mTc using the bifunctional chelating agent hydrazinonicotinamide (HYNIC). The radiochemical purity and in vitro stability of the probe were determined by HPLC. The binding activity was measured by western blotting (WB) and RT-PCR. The HABP1-overexpressing human ovarian cancer cell line HO-8910 was used for cell uptake experiments, which were performed with or without transfection and measured with a gamma counter. HO8910-bearing mice were imaged at 1, 4, and 10 h, and biodistribution analysis was performed at 1, 4, 6, and 10 h after injection of 99mTc-HYNIC-siRNA. 99mTc-HYNIC-siHABP1 had high radiochemical purity and good in vitro stability, and showed the same binding capacity and silencing effect as siHABP1. SPECT imaging showed that tumors were clearly visualized at 10 h after injection of 99mTc-HYNIC-siHABP1 but not after 99mTc-HYNIC-NCsiRNA, implying specific binding. The biodistribution results were consistent with those of SPECT imaging. We showed that 99mTc-HYNIC-siHABP1 is a feasible probe for the noninvasive visualization of HABP1 expression in ovarian cancer.
24 September 2026 in International Journal of Colorectal Disease
Objective: To develop and validate a positron emission tomography/computed tomography (PET/CT)-based model integrating clinical variables, body composition indices, and radiomics features for predicting lymph node metastasis (LNM) in colorectal cancer (CRC). Materials and methods: This retrospective study included 233 CRC patients who underwent preoperative 18 F-FDG PET/CT. Body composition parameters were quantified from CT images, and radiomics features were extracted from primary tumors on PET and CT images. Only preoperatively available clinical variables were included. Extreme Gradient Boosting (XGBoost) models based on clinical, body composition, and radiomics features were constructed in the training set and evaluated in an independent internal test set. Model performance was assessed using the area under the curve (AUC), DeLong test, and decision curve analysis. Results: LNM was present in 100/233 patients (42.9%). In the training set, multivariable logistic regression identified CEA, non-ulcerative macroscopic tumor type, PET/CT-reported lymph node status, and a lower SMA/SFA ratio as independent predictors of LNM. The integrated Body_Clinical_Radiomics model achieved an AUC of 0.794 (95% CI 0.724–0.860) in the training set and 0.780 (95% CI 0.659–0.887) in the internal test set. However, DeLong testing showed no statistically significant improvement over the Clinical_Radiomics model. Conclusion: The integrated PET/CT-based model showed promising performance for preoperative LNM prediction in CRC. SMA/SFA may provide complementary host-related information, although its incremental discriminatory value requires further validation.